FY2027 EPS Estimates for MeiraGTx Boosted by HC Wainwright

MeiraGTx Holdings PLC (NASDAQ:MGTX) – Investment analysts at HC Wainwright boosted their FY2027 earnings estimates for shares of MeiraGTx in a report released on Wednesday, July 8th. HC Wainwright analyst M. Kapoor now expects that the company will post earnings of $0.83 per share for the year, up from their previous forecast of $0.67. HC Wainwright has a “Buy” rating and a $20.00 price objective on the stock. The consensus estimate for MeiraGTx’s current full-year earnings is ($1.55) per share. HC Wainwright also issued estimates for MeiraGTx’s Q4 2027 earnings at $2.18 EPS.

MeiraGTx (NASDAQ:MGTX) last announced its earnings results on Thursday, May 14th. The company reported ($0.57) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.61) by $0.04. The business had revenue of $0.29 million for the quarter, compared to analyst estimates of $17.00 million.

MGTX has been the topic of a number of other research reports. Wall Street Zen raised MeiraGTx from a “sell” rating to a “hold” rating in a research report on Sunday, April 5th. Bank of America lifted their price objective on MeiraGTx from $14.00 to $16.00 and gave the company a “buy” rating in a report on Friday, March 27th. Chardan Capital reiterated a “buy” rating and set a $35.00 target price on shares of MeiraGTx in a research report on Friday, March 27th. Royal Bank Of Canada increased their target price on MeiraGTx from $25.00 to $26.00 and gave the stock an “outperform” rating in a report on Wednesday. Finally, Piper Sandler raised their price target on MeiraGTx from $26.00 to $30.00 and gave the stock an “overweight” rating in a research report on Wednesday, April 22nd. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $26.00.

MeiraGTx Trading Down 3.5%

NASDAQ MGTX opened at $14.14 on Thursday. MeiraGTx has a 1-year low of $6.62 and a 1-year high of $15.35. The company has a 50 day moving average of $10.51 and a 200-day moving average of $8.93. The company has a market cap of $1.31 billion, a price-to-earnings ratio of -9.55 and a beta of 1.20.

Hedge Funds Weigh In On MeiraGTx

Several hedge funds and other institutional investors have recently modified their holdings of the business. BNP Paribas Financial Markets raised its holdings in shares of MeiraGTx by 43.8% during the 2nd quarter. BNP Paribas Financial Markets now owns 4,810 shares of the company’s stock worth $31,000 after buying an additional 1,466 shares in the last quarter. Tower Research Capital LLC TRC boosted its stake in MeiraGTx by 390.9% in the second quarter. Tower Research Capital LLC TRC now owns 8,797 shares of the company’s stock valued at $57,000 after buying an additional 7,005 shares in the last quarter. ProShare Advisors LLC acquired a new stake in MeiraGTx in the fourth quarter valued at about $94,000. Abel Hall LLC acquired a new stake in MeiraGTx in the fourth quarter valued at about $98,000. Finally, Bank of Nova Scotia bought a new position in MeiraGTx in the first quarter valued at about $105,000. Institutional investors own 67.48% of the company’s stock.

Insider Buying and Selling

In related news, CEO Alexandria Forbes sold 62,000 shares of the stock in a transaction that occurred on Tuesday, May 19th. The shares were sold at an average price of $9.17, for a total transaction of $568,540.00. Following the sale, the chief executive officer owned 1,387,695 shares in the company, valued at approximately $12,725,163.15. This trade represents a 4.28% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Richard Giroux sold 56,000 shares of MeiraGTx stock in a transaction that occurred on Tuesday, April 21st. The shares were sold at an average price of $10.22, for a total transaction of $572,320.00. Following the completion of the transaction, the chief financial officer directly owned 971,530 shares in the company, valued at $9,929,036.60. This trade represents a 5.45% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 145,659 shares of company stock worth $1,550,213. Corporate insiders own 7.40% of the company’s stock.

About MeiraGTx

MeiraGTx Holdings plc is a clinical-stage biotechnology company dedicated to developing gene therapies for the treatment of rare diseases. Founded in 2014 as an outgrowth of research at University College London, the company focuses on leveraging adeno-associated virus (AAV) vectors to deliver functional genes to target tissues. MeiraGTx’s pipeline spans ocular, central nervous system and systemic indications, addressing conditions such as inherited retinal dystrophies and neurodegenerative disorders that currently lack effective therapies.

The company’s lead programs include AAV-based candidates designed to restore or replace defective genes underlying rare retinal diseases and to modulate cellular pathways in neurological disorders.